Skeletal muscle apoptosis in experimental heart failure: The only link between inflammation and skeletal muscle wastage?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 9, Issue 4, 2006, Pages 416-422

  Vescovo, Giorgio ^a   Libera, Luciano Dalla ^b  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Apoptosis; Experimental heart failure; Skeletal muscle; Ubiquitin proteasome

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CARNITINE; CASPASE 3; CASPASE 9; CYTOCHROME C; CYTOKINE; GROWTH HORMONE; INTERLEUKIN 1; LAMININ; MAMMALIAN TARGET OF RAPAMYCIN; MITOCHONDRIAL ENZYME; MONOCROTALINE; OXYGEN; PROTEASOME; PROTEIN BAX; PROTEIN BCL 2; SOMATOMEDIN C; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; SPHINGOSINE; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

APOPTOSIS; CACHEXIA; CELL LABELING; CONFOCAL MICROSCOPY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME RELEASE; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HEART FAILURE; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEYDIG CELL; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE FUNCTION; MYOSITIS; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PROTEIN SYNTHESIS; REVIEW; SECOND MESSENGER; SKELETAL MUSCLE;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 9; CYTOKINES; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746209090     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000232902.97286.35     Document Type: Review

References (42)

1. Coats AJS, Clark AL, Piepoli M, et al. Symptoms and quality of life in heart failure. The muscle hypothesis. Br Heart J 1994; 72:36-39.
2. Drexler H, Riede U, Munzel T, et al. Alterations of skeletal muscle in chronic heart failure. Circulation 1992; 85:1751-1759.
3. Vescovo G, Dalla Libera L, Serafini F, et al. Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 1998; 98:1742-1749.
4. Vescovo G, Serafini F, Facchin L, et al. Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis. Heart 1996; 76:337-343.
5. Vescovo G, Ceconi C, Bernocchi P, et al. Skeletal muscle myosin heavy chain expression in rats with monocrotaline-induced cardiac hypertrophy and failure. Relation to blood flow and degree of muscle atrophy. Cardiovasc Res 1998; 39:233-241.
6. Anker SD, Swan JW, Volterrani M, et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J 1997; 18:259-269.
7. Mancini DM, Reichek N, Chance B, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992; 85:1364-1373.
8. Anker SD, Rauchhaus M. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. Curr Opin Cardiol 1999; 14:211-216.
9. Skurk C, Izumiya Y, Maatz H, et al. The FOXO3 a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 2005; 280:20814-20823. This paper outlines the important mechanisms leading to hypertrophy and atrophy in the muscle through the Akt/FOXO/ubiquitin ligase system.
10. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117:399-412.
11. Vescovo G, Zennaro R, Sandri M, et al. Apoptosis of skeletal muscle myofibers and interstitial cells in experimental heart failure. J Mol Cell Cardiol 1998; 30:2449-2459.
12. Vescovo G, Volterrani M, Zennaro R, et al. Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart 2000; 84:431-437.
13. Anker SA, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001; 38:443-452.
14. Mann D, Reid M. Exercise training and skeletal muscle inflammation in chronic heart failure: feeling better about fatigue. J Am Coll Cardiol 2003; 42:869-872.
15. McKinnell IW, Rudnicki MA. Molecular mechanisms of muscle atrophy. Cell 2004; 119:907-910.
16. Pallafacchina G, Calabria E, Serrano AL, et al. A protein kinase B dependent and rapamycin sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci USA 2002; 99:9213-9218.
17. Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27:195-200.
18. Musaro A, Giacinti C, Borsellino G, et al. Stem cell mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci USA 2004; 101:1206-1210.
19. Dalla Libera L, Ravara B, Volterrani M, et al. Beneficial effects of Gh/IGF-1 on skeletal muscle atrophy and function in experimental heart failure. Am J Physiol Cell Physiol 2004; 286:C138-C144.
20. Puigserver P, Spiegelman BM. Peroxisome proliferators-activated receptor-g coactivator 1a (PGC-1a): transcriptional coactivator and metabolic regulator. Endocr Rev 2002; 24:78-90.
21. Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1a drives the formation of slow twitch muscle fibres. Nature 2002; 418:797-801.
22. Farber MO, Mannix ET. Tissue wasting in patients with chronic obstructive pulmonary disease. Neurol Clin 2000; 18:245-262.
23. Moldawer LL, Sattler FR. Human immunodeficiency virus-associated wasting and mechanisms of cachexia associated with inflammation. Semin Oncol 1998; 25:73-81.
24. Mann DL, Reid MB. Exercise training and skeletal muscle inflammation in chronic heart failure: feeling better about fatigue. J Am Coll Cardiol 2003; 42:869-872.
25. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell 1996; 87:13-20.
26. Meadows KA, Holly JM, Stewart CE. Tumor necrosis factor-alpha induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol 2000; 183:330-337.
27. Dalla Libera L, Sabbadini R, Renken C, et al. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine. J Mol Cell Cardiol 2001; 33:1871-1878.
28. Dalla Libera L, Zennaro R, Sandri M, et al. Apoptosis and atrophy in rat slow skeletal muscles in chronic heart failure. Am J Physiol Cell Physiol 1999; 277:C982-C986.
29. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 1999; 33:959-965.
30. Simon AM, Zittoun R. Fatigue in cancer patients. Curr Opin Oncol 1999; 11:244-249.
31. Li X, Moody MR, Engel D, et al. Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 2000; 102:1690-1696.
32. Dalla Libera L, Ravara B, Gobbo V, et al. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of carvedilol. J Mol Cell Cardiol 2005; 38:803-807. The first demonstration that oxidation of contractile proteins occurs in heart failure with consequent blunting of contractile efficiency. β-Blockers can prevent it.
33. Reid MB. Invited review: redox modulation of skeletal muscle contraction: what we know and what we don't. J Appl Physiol 2001; 90:724-731.
34. Reid MB, Li YP. Cytokines and oxidative signalling in skeletal muscle. Acta Physiol Scand 2001; 171:225-232.
35. Chamberlain JS. Cachexta in cancer zeroing in on myosin. N Engl J Med 2004; 351:2124-2125.
36. Schulze PC, Fang J, Kassik KA, et al. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibit ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 2005; 97:418-426. The paper elegantly demonstrates that IGF1, locally expressed, blocks ubiquitin and prevents atrophy.
37. Attaix D, Ventadour S, Codran A, et al. The ubiquitin-proteasome system and skeletal muscle wasting. In: Mayer M, Layfield R, editors. Essays in biochemistry, 41. London: Portland Press; 2005. pp.173-186. The alternative, non-ubiquitin-dependent proteolytic systems are described.
38. Vescovo G, Ravara B, Gobbo V, et al. L-carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am J Physiol Cell Physiol 2002; 283:C802-C810.
39. Dalla Libera L, Ravara B, Angelini A, et al. Beneficial effects on skeletal muscle of the Angiotensin II Type 1 receptor blocker Irbesartan in experimental heart failure. Circulation 2001; 103:2195-2200.
40. Dalla Libera L, Vescovo G. Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimaeric view of inflammation? Curr Opin Clin Nutr Metab Care 2004; 7:435-441.
41. Vescovo G, Ravara B, Angelini A, et al. Effect of thalidomide on the skeletal muscle in experimental heart failure. Eur J Heart Fail 2002; 4:455-460.
42. Vescovo G, Ravara B, Gobbo V, et al. Skeletal muscle fibres synthesis in heart failure: role of PGC-1α, calcineurin and GH. Int J Cardiol 2005; 104:298-306. It is demonstrated, for the first time, that in heart failure the growth hormone/IGF1/calcineurin/PGC1 system regulates fibre type and size expression.